Literature DB >> 27094906

Cancer chemoresistance; biochemical and molecular aspects: a brief overview.

Saeed Kachalaki1, Mina Ebrahimi2, Leila Mohamed Khosroshahi3, Sina Mohammadinejad4, Behzad Baradaran5.   

Abstract

The effectiveness of chemotherapy is one of the main challenges in cancer treatment and resistance to classic drugs and traditional treatment processes is an obstacle to this goal. Drug resistance that may be inherent or adventitious can cause poor treatment outcome and tumor relapse. In most cases, resistance to a drug can lead to resistance to many other drugs structure and function of which is not necessarily similar to the first drug. This phenomenon is the main mechanism behind failure of many of metastatic cancers. There are various molecular mechanisms involved in multidrug resistance, including change in the activity of membrane transporters (such as ABC transporters), increase of drug metabolism, change of the target enzyme (such as mutations that change thymidylate synthase and topoisomerases), promotion of DNA damage repair, and escape from drug induced apoptosis. Clinical and laboratory investigations on biomarkers involved in the response to chemotherapy have characterized the key factors behind the failure of treatments. Knowing the molecular factors involved in drug resistance may help us to develop new strategies for more promising chemotherapy and reduce the rate of relapse. In this brief review, molecular mechanisms and tumor microenvironment leading to decreased drug sensitivity, and strategies of reversing drug resistance are described.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Drug resistance; Drug sequestration; Molecular mechanism; Sensitivity; Tumor microenvironment

Mesh:

Substances:

Year:  2016        PMID: 27094906     DOI: 10.1016/j.ejps.2016.03.025

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  38 in total

1.  P53/PUMA are potential targets that mediate the protection of brain-derived neurotrophic factor (BDNF)/TrkB from etoposide-induced cell death in neuroblastoma (NB).

Authors:  Zhongyan Hua; Yue Zhan; Simeng Zhang; Yudi Dong; Min Jiang; Fei Tan; Zhihui Liu; Carol J Thiele; Zhijie Li
Journal:  Apoptosis       Date:  2018-08       Impact factor: 4.677

Review 2.  Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy.

Authors:  Kinsie E Arnst; Souvik Banerjee; Hao Chen; Shanshan Deng; Dong-Jin Hwang; Wei Li; Duane D Miller
Journal:  Med Res Rev       Date:  2019-02-11       Impact factor: 12.944

3.  Assessment of a bifendate derivative bearing a 6,7-dihydro-dibenzo[c,e]azepine scaffold as a potential anti-metastatic agent.

Authors:  Jingying Qiu; Wang Chen; Yanfei Jiang; Jing Chen; Yinpeng Zhang; Xiaoke Gu
Journal:  Medchemcomm       Date:  2018-09-17       Impact factor: 3.597

4.  Hepatitis B X-interacting protein promotes cisplatin resistance and regulates CD147 via Sp1 in ovarian cancer.

Authors:  Wei Zou; Xiangdong Ma; Hong Yang; Wei Hua; Biliang Chen; Guoqing Cai
Journal:  Exp Biol Med (Maywood)       Date:  2017-01-05

5.  P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors.

Authors:  Chengqiong Mao; Yan Zhao; Fang Li; Zibo Li; Shaomin Tian; Waldemar Debinski; Xin Ming
Journal:  J Control Release       Date:  2018-08-04       Impact factor: 9.776

6.  A review of drugs in development for the personalized treatment of head and neck squamous cell carcinoma.

Authors:  Andrew C Birkeland; Paul L Swiecicki; J Chad Brenner; Andrew G Shuman
Journal:  Expert Rev Precis Med Drug Dev       Date:  2016-07-15

7.  Encorafenib enhances TRAIL-induced apoptosis of colorectal cancer cells dependent on p53/PUMA signaling.

Authors:  Zhenqing Sun; Zhigang Qiu; Bin Ma; Zhengkun Wang
Journal:  Cytotechnology       Date:  2020-11-13       Impact factor: 2.058

Review 8.  Cell fusion in cancer hallmarks: Current research status and future indications.

Authors:  Hao-Fei Wang; Wei Xiang; Bing-Zhou Xue; Yi-Hao Wang; Dong-Ye Yi; Xiao-Bing Jiang; Hong-Yang Zhao; Peng Fu
Journal:  Oncol Lett       Date:  2021-05-16       Impact factor: 2.967

9.  The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer.

Authors:  F Guffanti; R Fruscio; E Rulli; G Damia
Journal:  Sci Rep       Date:  2016-12-01       Impact factor: 4.379

10.  Identification of chemoresistance-associated microRNAs and hub genes in breast cancer using bioinformatics analysis.

Authors:  Ming Wu; Yujie Zhao; Nanxi Peng; Zuo Tao; Bo Chen
Journal:  Invest New Drugs       Date:  2021-01-04       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.